Novus Reports Q3 2026 Financial Growth and Expands Cannabis Health Plan Provider Network
Found this article helpful?
Share it with your network and spread the knowledge!

Novus Acquisition & Development Corp. (OTC: NDEV), operating through its subsidiary WCIG Insurance Services, Inc. as Novus Cannabis MedPlan, released interim financial results for the nine-month period ending September 30, 2026, reporting stable operational margins, disciplined capital management, and continued expansion of its health insurance and benefits administrative platform. The company, which operates strictly as a health plan carrier and benefits administrator, derives all revenues from member plan fees and insurance premiums rather than the direct sale of controlled substances.
For the period, Novus reported a 7.78% year-over-year increase in gross revenue, a 2.34% year-to-date expansion in total assets, and a 2.26% year-to-date increase in stockholders’ equity. The company maintained a highly unleveraged capital structure with a debt-to-equity ratio of 9.74% and 0% convertible debt among its total liabilities. Corporate governance mandates remain strictly enforced, with 0% insider share liquidation over the trailing 36-month period and a 100% active Vendor Share Leak-Out Provision to mitigate market dilution.
The financial disclosure arrives as medical marijuana emerges as a primary alternative healthcare focus for an estimated 65 million Americans. Novus is positioning itself to accommodate this demographic shift through its scaling provider network. To meet stringent corporate and institutional standards, Novus Cannabis MedPlan has onboarded a new commercial provider, Upscale (www.shopupscalecbd.com). Upscale delivers institutional-grade, broad-spectrum, THC-free formulations manufactured in an NSF GMP-compliant facility in Phoenix, Arizona. The brand’s portfolio is underpinned by the rigorous NSF Certified for Sport designation, a credential that supports compliance frameworks and facilitates strategic alignment within high-performance and regulated athletic environments, helping NDEV expand its corporate distribution channels while maintaining disciplined risk management protocols.
For capital markets, NDEV’s intrinsic value is driven by its proprietary dual-platform infrastructure and non-plant-touching business model. The company maintains 100% operational segregation between its prescription drug plan and its cannabis-adjacent distribution platform. By strictly managing access and never touching the cannabis plant itself, Novus operates independently of federal cannabis scheduling delays and avoids the heavy tax burdens of Internal Revenue Code Section 280E. This structure enables greater cost efficiency for policyholders, with a net 25% to 30% reduction in gross out-of-pocket expenditure at the point of sale achieved through direct product discounting and pre-tax purchasing power. Members receive an immediate 35% to 40% discount on verified medicinal cannabis products at the register, and utilizing Health Savings Accounts (HSA) or Flexible Spending Accounts (FSA) allows members to pay for eligible healthcare and insurance expenses using pre-tax dollars, corresponding to an estimated 15% to 17% reduction in effective tax liability.
By transitioning alternative medicine from the retail shelf to the structured benefits ledger, NDEV continues to build a resilient, non-cyclical market position. For comprehensive financial statements, Management Discussion and Analysis, and Q3 2026 highlights, the company directs investors to its https://www.getnovusnow.com/investor-relations portal. Financial filings are also available through the Click Here link, and current quote information can be accessed via the Click Here link.
